Overview G-Pen™ for Hypoglycemia Rescue in T1D Patients Status: Completed Trial end date: 2015-06-01 Target enrollment: Participant gender: Summary This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart. Subjects will receive a single injection of G-Pen™ (glucagon injection) at each visit. Phase: Phase 2 Details Lead Sponsor: Xeris PharmaceuticalsTreatments: GlucagonGlucagon-Like Peptide 1